| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Advancing the treatment of juvenile idiopathic arthritis
|
Murray, Grainne M
|
|
|
3 |
4 |
p. e294-e305
|
artikel
|
| 2 |
Communication combats hesitancy
|
The Lancet Rheumatology,
|
|
|
3 |
4 |
p. e235
|
artikel
|
| 3 |
Correction to Lancet Rheumatol 2020; 2: e677–88
|
|
|
|
3 |
4 |
p. e250
|
artikel
|
| 4 |
Correction to Lancet Rheumatol 2020; 2: e666–76
|
|
|
|
3 |
4 |
p. e250
|
artikel
|
| 5 |
Correction to Lancet Rheumatol 2021; 3: e111–21
|
|
|
|
3 |
4 |
p. e250
|
artikel
|
| 6 |
COVID-19 cytokine storm: targeting the appropriate cytokine
|
Cron, Randy Q
|
|
|
3 |
4 |
p. e236-e237
|
artikel
|
| 7 |
Hacking the inflammatory reflex
|
Tracey, Kevin J
|
|
|
3 |
4 |
p. e237-e239
|
artikel
|
| 8 |
Interleukin-1 and interleukin-6 inhibition compared with standard management in patients with COVID-19 and hyperinflammation: a cohort study
|
Cavalli, Giulio
|
|
|
3 |
4 |
p. e253-e261
|
artikel
|
| 9 |
Interleukin-1 and interleukin-6 inhibition in patients with COVID-19 and hyperinflammation
|
Salvatierra, Juan
|
|
|
3 |
4 |
p. e248
|
artikel
|
| 10 |
Interleukin-1 and interleukin-6 inhibition in patients with COVID-19 and hyperinflammation – Authors' reply
|
Cavalli, Giulio
|
|
|
3 |
4 |
p. e248-e249
|
artikel
|
| 11 |
Long-term safety and efficacy of tofacitinib up to 48 months in psoriatic arthritis
|
Strand, Vibeke
|
|
|
3 |
4 |
p. e239-e240
|
artikel
|
| 12 |
Non-invasive vagus nerve stimulation for rheumatoid arthritis: a proof-of-concept study
|
Marsal, Sara
|
|
|
3 |
4 |
p. e262-e269
|
artikel
|
| 13 |
Perspective of patients with autoimmune diseases on COVID-19 vaccination
|
Boekel, Laura
|
|
|
3 |
4 |
p. e241-e243
|
artikel
|
| 14 |
Poor phase 4 safety results for tofacitinib raise questions about JAK inhibitors
|
Owens, Brian
|
|
|
3 |
4 |
p. e252
|
artikel
|
| 15 |
Research in Brief
|
Thorley, Jennifer
|
|
|
3 |
4 |
p. e251
|
artikel
|
| 16 |
Safety and efficacy of tofacitinib up to 48 months in patients with active psoriatic arthritis: final analysis of the OPAL Balance long-term extension study
|
Nash, Peter
|
|
|
3 |
4 |
p. e270-e283
|
artikel
|
| 17 |
The impact of autoantibodies against citrullinated, carbamylated, and acetylated peptides on radiographic progression in patients with new-onset rheumatoid arthritis: an observational cohort study
|
Nijjar, Jagtar S
|
|
|
3 |
4 |
p. e284-e293
|
artikel
|
| 18 |
The unsustainable bubble of disease-modifying antirheumatic drugs in rheumatology
|
Landewé, Robert B M
|
|
|
3 |
4 |
p. e306-e312
|
artikel
|
| 19 |
Type I interferon, anti-interferon antibodies, and COVID-19
|
Calabrese, Leonard H
|
|
|
3 |
4 |
p. e246-e247
|
artikel
|
| 20 |
Vaccination against COVID-19: Expectations and concerns of patients with autoimmune and rheumatic diseases
|
Felten, Renaud
|
|
|
3 |
4 |
p. e243-e245
|
artikel
|
Tijdschrift beschrijving